Vium Announces First Peer-Reviewed Publication for its Digital Vivarium Technology

SAN MATEO, Calif.--(BUSINESS WIRE)-- VIUM , a preclinical drug discovery platform company, announced today the publication of a peer reviewed paper in the journal Frontiers in Pharmacology.

The article titled “Development of the Digital Arthritis Index, a Novel Metric to Measure Disease Parameters in a Rat Model of Rheumatoid Arthritis”, describes the development of an automated scoring system for measuring Rheumatoid Arthritis (RA) in preclinical rodent studies avoiding the use of manual measurements, improving the collection of data and reproducibility of studies. The paper can be accessed online at https://www.frontiersin.org/articles/10.3389/fphar.2017.00818/full.

The authors describe the use of Vium’s Digital Vivarium technology to develop a Digital Arthritis Index (DAI), an objective and automated behavioral metric that does not require manual measurement or calculation of disease parameters. The validity of the metric was demonstrated by its ability to track similarly to standard methods of assessing arthritis across several independent experiments and multiple standard of-care (SOC) RA drugs with a high degree of reproducibility and prediction.

“We are pleased to have published this first peer-reviewed article demonstrating the predictive power of using computer vision to analyze disease progression and treatment,” said David Hutto, Vium’s Chief Scientific Officer. “The ability to non-invasively obtain longitudinal health and behavioral data 24/7 is analogous to the work that is happening in the clinical setting with wearable technologies. The development of the Digital Arthritis Index demonstrates the potential for the Vium platform to reduce the reliance on manual observations, saving time and improving the efficiency of in vivo drug testing while at the same time enabling new insights to help advance clinical candidates.”

About Vium, Inc.

Vium has developed the world’s first Digital Vivarium®, a fully integrated hardware and software platform for preclinical in vivo drug research and development that operates at scale. The platform, incorporating Vium Smart Housing™, Vium Cloud infrastructure, and Research Suite software, empowers scientists to optimize in vivo disease research and advance drug development. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the “3 Rs,” the gold-standard framework for humane animal research. Customers include pharmaceutical, biotechnology and computational drug discovery companies, academia and health science research centers. Vium is backed by leading investors, including Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, and Founders Fund.

Vium is headquartered in San Mateo, California. For more information, please visit www.vium.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005364/en/